Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Launched by UNIVERSITY OF VIRGINIA · Jul 19, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the impact of early and ongoing palliative care for patients with certain types of leukemia and myelodysplastic syndromes (MDS). Palliative care is a specialized type of medical care that focuses on providing relief from symptoms and improving the quality of life for patients with serious illnesses. The goal of this study is to see how this type of care can help patients and their families deal with end-of-life issues, especially for those who are facing relapsed or high-risk forms of these blood cancers.

To be eligible for the study, participants need to be at least 65 years old with a new diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk MDS. Alternatively, younger patients aged 18 and older with relapsed or refractory (or hard-to-treat) AML, ALL, or high-risk MDS may also qualify. Participants will be required to give their consent and be available for the study procedures throughout its duration. If you or someone you know might be interested in this trial, it's important to note that patients with a specific type of leukemia called Acute Promyelocytic Leukemia (APL) are not eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ability to provide informed consent
• • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
• 3. Any of the following:
• • 1. Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.
• • OR
• • 2. Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
• • OR
• • 3. Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
• • Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.
• • Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.
• Exclusion Criteria:
• • 1. Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)